- Home
- category
- DIASAGE (DIABETIC)
- DIASAGE (DIABETIC)
- Empasug-LG 25mg
Empasug-LG 25mg
Manufactured By Intra Life
product type tab
Composition Empagliflozin 25 mg + Linagliptin 5 mg IR
Package SIZE
( 10X10 )
100% Authentic
Products
Free
Shipping
Products
Return Policy
Information about Empasug-LG 25mg
Description:
- Empasug-LG 25mg is a fixed-dose oral antihyperglycemic agent combining empagliflozin (25 mg) and linagliptin (5 mg). This dual-mechanism tablet is indicated for adults with type 2 diabetes mellitus (T2DM) to improve glycemic control. The combination leverages SGLT2 inhibition to promote urinary glucose excretion and DPP-4 inhibition to enhance insulin secretion and suppress glucagon. It is not indicated for type 1 diabetes or diabetic ketoacidosis.
- As one of the trusted choices among empagliflozin tablet manufacturers, this formulation ensures consistent quality and clinical effectiveness.
Key Features:
-
Combines empagliflozin and linagliptin for complementary glycemic control
-
Supports HbA1c reduction and improved postprandial glucose regulation
-
Demonstrates cardiovascular and renal protection in clinical settings
-
Provides a once-daily oral dosing schedule to improve patient compliance
-
Well-suited for patients requiring dual antihyperglycemic therapy
- Widely recommended by diabetes medicine wholesalers due to its effective dual-action mechanism
Usage Guidelines:
-
Take once daily, with or without food
-
Initiate therapy in adults not adequately controlled on monotherapy
-
Monitor renal function and glycemic response during use
Safety Profile:
-
Side effects may include nasopharyngitis, urinary tract infections, or headaches
-
Avoid in patients with eGFR <30 mL/min/1.73m², type 1 diabetes, or ketoacidosis
-
Monitor for ketoacidosis, hypovolemia, and signs of pancreatitis
Uses / Indications: Used in adults with type 2 diabetes mellitus (T2DM) to improve blood sugar control as an adjunct to diet and exercise. This combination of SGLT2 inhibitor (Empagliflozin) and DPP-4 inhibitor (Linagliptin) provides dual glucose-lowering effects. Not for type 1 diabetes or diabetic ketoacidosis.